Results

Total Results: 406 records

Showing results for "company".

81. Woolf_ECCS2012 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/woolf_eccs2012.pdf
    January 01, 2012 - Woolf_ECCS2012 Slide 1: Discussion 1: When Conventional Wisdom, Clinical Policy/Practice, and  Evidence  Collide Steven H.  Woolf, M.D.,  M.P.H. Professor of Family Medicine Virginia Commonwealth University, Richmond, Virginia Slide 2: U.S. Preventive Services  Ta…

82. Disposition of Comments Report for Evaluation and Treatment of Tinnitus (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/tinnitus_disposition-comments.pdf
    August 23, 2013 - Also, Neuromonics is the only method of tinnitus management that refers to a company. … This method should be mentioned separately because it is a for- profit company and not just a “method … ” that anyone can use (any implementation of Neuromonics requires company training and support). … , all articles written about Neuromonics are written by people who are somehow affiliated with the company … on this paper is the inventor of Neuromonics and continues to work a consultant for the Neuromonics company

83. Use of and access to health care by Medicare beneficiaries with diabetes: impact of diabetes type and insulin use, 2007-2011 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-medicare-use_research.pdf
    January 01, 2014 - Health, Division of Health Policy and Management, Min- neapolis, MN. 2 Buccaneer, A General Dynamics company … Buccaneer, a General Dynamics Company. Chronic Conditions Data Warehouse. … Buccaneer, a General Dynamics Company. Chronic Conditions Data Warehouse: Condition categories.

84. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/dementia_horizon-scan-high_impact-1306-revised.pdf
    July 09, 2013 - is ongoing for flutemetamol while another phase III trial has been completed.12,13 According to a company … Indianapolis (IN): Eli Lilly and Company; 2012 Apr 6 [accessed 2012 May 10]. [4 p]. … Indianapolis (IN): Eli Lilly and Company; 2012 Apr. 11 p. … Eli Lilly and Company.

85. Disposition of Comments Report for Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/asthma-immunotherapy-2010_disposition-comments.pdf
    January 01, 2010 - a result of this partial evidence of efficacy from this small clinical trial, the pharmaceutical company

86. PULMONARY with "Discussions" in Exec Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1412.pdf
    October 01, 2015 - In November 2014, the company submitted a new drug application (NDA)to FDA for a fixed-dose combination … In October 2014, the manufacturer announced the company had implemented a patient support program … In November 2014, the company submitted a new drug application to the U.S. … approved nintedanib for treating IPF.31 Diffusion: In October 2014, Boehringer Ingelheim announced the company … financial resources, the program will cover the entire cost of therapy.32 Additionally Roche stated the company

87. PULMONARY with "Discussions" in Exec Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pulmonary_hi_impact.pdf
    April 01, 2012 - In October 2011, the company submitted a new drug application to FDA with a request for priority review … serious adverse events with ivacaftor than with placebo (24% vs. 42%). 25 In October 2011, the company … request for priority review, which would shorten the anticipated review time by 4 months. 26 The company

88. 08 Functional Limitations Potential High Impact 2012-12-10 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/08_functional_limitations_potential_high_impact_2012-12-10.pdf
    January 01, 2012 - The company expected to register the ReWalk-P system for personal use with FDA in the near future. … a way forward, the manufacturer resubmitted the NDA for Levadex in October 2012 to FDA. 111 The company … the original BLA after FDA stated that it would grant ocriplasmin priority review status, and the company … According to a published report, the company expects to soon register ReWalk-P for personal use for … New York (NY): Fast Company; 2012 Mar 19 [accessed 2012 Mar 30]. [8 p].

89. Obesity (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1512.pdf
    December 01, 2015 - The company must also conduct multiple postmarketing studies for liraglutide: trials to evaluate dosing … The company is also conducting a cardiovascular outcomes trial.67,68 FDA approved liraglutide injection … sales representatives to heavily promote Saxenda for obesity treatment in the United States.71 The company … New York (NY): The New York Times Company; 2012 Apr 10 [accessed 2013 Feb 01]. [3 p]. … Novo Nordisk - a focused healthcare company.

90. Ch 8-User-Guide-To-Ocer 130129 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/ch_8-user-guide-to-ocer_130129.pdf
    October 01, 2013 - Claims submitted to the insurance company use the NDC as the identifier of the product. … On the other hand, if the data resource pulls information from a switch company (an organization that … specializes in routing claims between the point of service and an insurance company), there may be

91. Arthritis and Nontraumatic Joint Disease (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/arthritis_hi_impact.pdf
    January 01, 2014 - The company announced that the drug's wholesale acquisition cost would be $2,300 per 8mg vial, which … The company started phase III trials of a subcutaneous formulation in December 2011. … included injection-site reaction, infection, musculoskeletal pain/discomfort, and headache. 23 The company … active, autoantibody-positive SLE who are receiving standard therapy. 86 In December 2011, the company … Eli Lilly and Company. A study of LY2127399 in patients with systemic lupus erythematosus.

92. Arthritis and Nontraumatic Joint Disease (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1412.pdf
    December 01, 2014 - The company is preparing U.S. … with gout who are intolerant of or who have contraindications for xanthine oxidase inhibitors.10 The company

93. Moyer_ECCS2012 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/moyer_eccs2012.pdf
    January 01, 2012 - Moyer_ECCS2012 Slide 1:  When Evidence-­‐Based Recommendations  Collide  With Conventional   Wisdom: Lessons  in Communication Learned by the U.S. Preventive Services   Task Force Virginia A. Moyer, M.D., M.P.H. Professor of Pediatrics Baylor College of Medicine,  Houston,  TX …

94. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/recombinant-factor-viia_disposition-comments.pdf
    June 01, 2010 - I have queried the company on several occasions about their market in the US. … I have no reason to doubt this statement -- perhaps the reviewers could get actual data from the company … Methods Methods Given Danish manufacturing company, limiting search to English language is debatable … Methods Re: scoring of affiliation with the company.

95. Colon-Cancer-Gene-Profiling Research-Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/colon-cancer-gene-profiling_research-protocol.pdf
    March 13, 2012 - clinical indications will be abstracted from guidelines and reviews in the medical literature and from company

96. Medicare-Medication-Use Research (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/medicare-medication-use_research.pdf
    April 01, 2014 - Health, Division of Health Policy and Management, Minneapolis, MN. 3 Buccaneer, A General Dynamics company … Buccaneer, a General Dynamics Company. … Buccaneer, a General Dynamics Company. Chronic conditions data warehouse: data dictionaries.

97. PEPTIC ULCER #11 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/11_peptic_ulcer_potential_high_impact_2012-12-111.pdf
    January 01, 2012 - The company recommends a starting dose of 500 ova, taken orally once every 1–3 weeks, with titration … The company notes that initial response may require several weeks and, because helminths are short-lived … The company requires a letter from a physician and a statutory declaration from the importer stating … that the worms are for personal use and constitute 3 months or fewer of treatment. 4 The company

98. #06 Developmental Delays ADHD, and Autism (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1406.pdf
    June 01, 2014 - off-label, intranasal oxytocin for treating social cognitive deficits in patients with ASD, and one company

99. Research White Paper Patient- or Participant-Generated Registries Addendum Registries for Evaluating Patient Outcomes Third Edition (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/patient-participant-generated-registries-guide-3rd-ed-addendum-white-paper.pdf
    February 01, 2018 - streamline processes, and conduct research studies as part of PCORnet.88 PatientsLikeMe is a for profit company … (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract

100. Crosscutting-Horizon-Scan-High-Impact-1512 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - The company received FDA clearance through the 510(k) process for the monitoring device in March 2010 … adverse events related to the device, of which three were skin rashes and one was nausea.7 The company … tablets; they jointly submitted a new drug application in September 2015.14 In August 2010, the company … Clinical Pathway at Point of This Intervention The company states that tablets can be delivered to patients